The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer
Official Title: Combinational Therapy of Capecitabine, Lapatinib and Vinorelbine for the Treatment of Patients With her2/Neu Positive, Relapsed or Metastatic Breast Carcinoma Following Treatment Failure With Trastuzumab
Study ID: NCT01238029
Brief Summary: The purpose of the study is to investigate safety and efficiency of the triple combination of capecitabine, lapatinib and vinorelbine in patients with metastatic breast cancer.
Detailed Description: The combination of lapatinib with capecitabine ist a standard therapy für Her2 positive metastatic breast cancer. This study combines this therapy with the additional antimitotic mode of function by vinorelbine.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Onkologie Ravensburg, Ravensburg, Baden-Württemberg, Germany
Praxisgemeinschaft Dres. Siehl und Söling, Kassel, Hessen, Germany
Onkologische Schwerpunktpraxis, Goslar, Niedersachsen, Germany
Onkologische Schwerpunktpraxis Leer Emden, Leer, Niedersachsen, Germany
Schwerpunktpraxis Hämatologie / Onkologie, Stade, Niedersachsen, Germany
Onkodok (Dr. Rösel und Dr. Depenbusch), Guetersloh, Nordrhein-Westfalen, Germany
Praxis für Hämatologie und Onkologie, Mulheim an der Ruhr, Nordrhein-Westfalen, Germany
Hämatologisch-onkologische Gemeinschaftspraxis, Münster, Nordrhein-Westfalen, Germany
Praxis für Onkologie u. Hämatologie, Neuss, Nordrhein-Westfalen, Germany
Onkologische Gemeinschaftspraxis Dörfel/Göhler, Dresden, Saxony, Germany
Onkologische Schwerpunktpraxis, Heidelberg, , Germany
Name: Ulrike Soeling, MD
Affiliation: Goethestr. 47, 34119 , Kassel, Germany
Role: PRINCIPAL_INVESTIGATOR